Name - Immuron Limited
Current / Former Name: Immuron Limited (Current)
Address: Unit 10, 25-37 Chapman Street, Blackburn North, VIC 3130, Australia
Phone Number: +61 3 9824 5254
Investor Relations Contact: info@immuron.com
Website - https://www.immuron.com
Warrant Details
Warrant Symbol: IMRNW
Warrants Listed: 2,750,000
Ratio: 1-for-1
Cusip Number: 45256A 11 0
ISIN Number: US45256A1100
Parent Stock Symbol: IMRN (NASDAQ)
Underlying Stock CUSIP: 45256A 10 2
Expiry Date - June 13, 2022
Exercise Price: $10.00 USD
Synopsis & Listing Information
Immunovant Inc. is a clinical-stage biopharmaceutical enterprise dedicated to developing targeted therapies for autoimmune diseases driven by pathogenic IgG antibodies, utilizing its lead asset batoclimab.
Listing History: Immunovant became a publicly traded entity via its business combination with the SPAC Health Sciences Acquisitions Corp. on December 18, 2019. The public warrants subsequently commenced trading on the Nasdaq Capital Market under the identifier IMVTW.
Business Combination / Liquidation: Following successful clinical advancement, the company executed a strategic corporate action to eliminate its outstanding warrant liability overhang.
Ticker Change: N/A
Reverse Split Adjustment: N/A
Current Status: Immunovant successfully exercised its right to call all outstanding public warrants for redemption. The redemption process was finalized, resulting in either the cashless exercise or cancellation of the tranches. The symbol IMVTW is fully delisted and inactive.
Current / Former Name: Immuron Limited (Current)
Address: Unit 10, 25-37 Chapman Street, Blackburn North, VIC 3130, Australia
Phone Number: +61 3 9824 5254
Investor Relations Contact: info@immuron.com
Website - https://www.immuron.com
Warrant Details
Warrant Symbol: IMRNW
Warrants Listed: 2,750,000
Ratio: 1-for-1
Cusip Number: 45256A 11 0
ISIN Number: US45256A1100
Parent Stock Symbol: IMRN (NASDAQ)
Underlying Stock CUSIP: 45256A 10 2
Expiry Date - June 13, 2022
Exercise Price: $10.00 USD
Synopsis & Listing Information
Immunovant Inc. is a clinical-stage biopharmaceutical enterprise dedicated to developing targeted therapies for autoimmune diseases driven by pathogenic IgG antibodies, utilizing its lead asset batoclimab.
Listing History: Immunovant became a publicly traded entity via its business combination with the SPAC Health Sciences Acquisitions Corp. on December 18, 2019. The public warrants subsequently commenced trading on the Nasdaq Capital Market under the identifier IMVTW.
Business Combination / Liquidation: Following successful clinical advancement, the company executed a strategic corporate action to eliminate its outstanding warrant liability overhang.
Ticker Change: N/A
Reverse Split Adjustment: N/A
Current Status: Immunovant successfully exercised its right to call all outstanding public warrants for redemption. The redemption process was finalized, resulting in either the cashless exercise or cancellation of the tranches. The symbol IMVTW is fully delisted and inactive.
American Financial News
Loading the latest American market news...
American Financial News
Loading the latest American market news...